IPRASENSE

Their core work

IPRASENSE is a French SME specializing in advanced optical instrumentation and biophotonics imaging systems for life sciences applications. They develop label-free microscopy technologies — including quantitative phase imaging and 3D refractive index microscopy — that allow non-destructive, non-staining analysis of living cells and biological samples. Beyond imaging hardware, they integrate machine learning to automate the interpretation of complex biological image data. In industrial settings, they have contributed at-line and on-line optical sensors for monitoring biopharmaceutical cultivation processes in high-throughput bioreactors.

What they specialise in

How they've shifted over time

In their first H2020 project (2018), IPRASENSE focused on process analytical technology — deploying optical sensors to monitor biopharmaceutical production in real time, a fundamentally industrial and manufacturing-oriented application. By their second project (2021), the focus had shifted clearly toward research-grade microscopy: quantitative phase imaging, label-free cell visualization, and neural network-driven analysis for neuroscience. The trajectory suggests a deliberate move from inline process sensing toward high-content biological imaging platforms, with machine learning becoming a core component of their offer.

IPRASENSE is moving toward intelligent, AI-augmented label-free microscopy for cell biology and neuroscience research, expanding beyond industrial bioprocess monitoring into high-content imaging platforms.

How they like to work

IPRASENSE has participated exclusively as a consortium partner — never as project coordinator — suggesting they prefer contributing focused instrumentation expertise to projects shaped by academic or clinical leads. Despite only two projects, they have engaged with 28 distinct partners, which points to participation in large, multi-actor consortia rather than tight bilateral arrangements. This profile fits a specialist hardware-and-software provider that slots into collaborative projects where no single partner can build the full measurement stack alone.

With 28 unique consortium partners across 9 countries in just two projects, IPRASENSE operates within sizeable multi-partner consortia spanning Western Europe. No single dominant partner country is evident from this small dataset, suggesting broad European integration rather than a bilateral research relationship.

What sets them apart

IPRASENSE occupies a narrow but high-value niche: compact SME-scale optical instrumentation that spans both upstream bioprocess monitoring and downstream cell research microscopy. Very few commercial players combine label-free quantitative phase imaging with machine learning interpretation at this scale, making them a credible technology provider for consortia that need measurement hardware rather than just computational methods. For project coordinators in health or digital sectors, they offer an industrially grounded optics team that can build and deploy prototype sensing systems — something most university partners cannot.

Highlights from their portfolio

• REVEAL
  Their largest and most recent project (EUR 298,750), combining biophotonics microscopy with neural networks for neuronal cell analysis — the clearest signal of their current technical direction.
• iConsensus
  Their H2020 entry point, demonstrating industrial optical sensing competence in biopharmaceutical high-throughput cultivation — a distinct application domain from REVEAL that shows breadth across the life sciences measurement chain.